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Background: Extensive reprogramming and dysregulation of DNA methylation is an important characteristic of
pancreatic cancer (PC). Our study aimed to characterize the genomic methylation patterns in various genomic
contexts of PC. The methyl capture sequencing (methylCap-seq) method was used to map differently methylated
regions (DMRs) in pooled samples from ten PC tissues and ten adjacent non-tumor (PN) tissues. A selection of DMRs
was validated in an independent set of PC and PN samples using methylation-specific PCR (MSP), bisulfite sequencing
PCR (BSP), and methylation sensitive restriction enzyme-based qPCR (MSRE-qPCR). The mRNA and expressed sequence
tag (EST) expression of the corresponding genes was investigated using RT-qPCR.
Results: A total of 1,131 PC-specific and 727 PN-specific hypermethylated DMRs were identified in association with CpG
islands (CGIs), including gene-associated CGIs and orphan CGIs; 2,955 PC-specific and 2,386 PN-specific hypermethylated
DMRs were associated with gene promoters, including promoters containing or lacking CGIs. Moreover, 1,744
PC-specific and 1,488 PN-specific hypermethylated DMRs were found to be associated with CGIs or CGI shores.
These results suggested that aberrant hypermethylation in PC typically occurs in regions surrounding the transcription
start site (TSS). The BSP, MSP, MSRE-qPCR, and RT-qPCR data indicated that the aberrant DNA methylation in PC tissue
and in PC cell lines was associated with gene (or corresponding EST) expression.
Conclusions: Our study characterized the genome-wide DNA methylation patterns in PC and identified DMRs that
were distributed among various genomic contexts that might influence the expression of corresponding genes or
transcripts to promote PC. These DMRs might serve as diagnostic biomarkers or therapeutic targets for PC.
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Pancreatic cancer (PC), a highly malignant tumor of the
digestive system, is a type of solid tumor that currently
has one of the worst prognoses, with a postoperative
5-year survival rate of less than 25%. Nearly 100,000
people die from PC every year in the USA and Europe;
PC ranks fourth and fifth for cancer mortality in those* Correspondence: yujian@shsci.org
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unless otherwise stated.countries, respectively [1]. The incidence of PC in China
is also displaying an increasing trend [2].
From a biological perspective, genetics is predomin-
antly responsible for the stable transfer of hereditary
information between generations, whereas the distinct
somatic phenotypes in different tissues and cells are
influenced by epigenetics. Because most tumors that de-
velop display particular acquired biological phenotypes,
epigenetic changes must surely play important roles
during tumor development [3]. DNA methylation, a
well-studied epigenetic phenomenon, has already been
extensively studied in PC. At the gene particular level,
genes such as p14ARF and p16INK4a [4,5] were foundtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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abnormalities in gene transcription. At the genomic level,
by combining the techniques of methylated CGI amplifica-
tion with Agilent 244 K Human Promoter ChIP-on-chip
microarrays, the genome-wide methylation abnormalities
in PC have been identified [6,7].
However, methylation array technology platform-based
studies are typically focused on CpG islands (CGIs) and
presumably provide less coverage of the entire genome
than studies using next-generation sequencing technology
[8]. Therefore, the details of the genome-wide methylation
profile of PC reported by these studies should be supple-
mented further, especially in regions such as CGI shores
(2 kb regions flanking a CGI), non-CGI promoter regions,
and non-gene-associated CGIs (orphan CGIs), as it has
already been suggested that methylation changes in these
particular regions are associated with certain tumor
phenotypes or with tissue specificity [9,10].
In light of these next-generation sequencing technologies,
the methylated portion of the genome identified using
methyl capture sequencing (methylCap-seq) [11] has
been profiled in greater detail than using an array-based
platform, revealing many novel regions that are differ-
ently methylated in a biological sample. Here, we report
a comparison of global DNA methylation patterns be-
tween pooled PC tissue and pooled adjacent (PN) tissue
samples to identify the critical epigenetic effectors re-
sponsible for the malignant phenotype of PC. Our study
characterized the genome-wide methylation profile of
PC and identified the genomic regions displaying a high
frequency of aberrant methylation, including regions of
gene-associated CGIs, orphan CGIs, CpG shores, and
gene promoters lacking CGIs. The aberrant DNA methy-
lation that occurred in these regions was separated into
two categories: aberrant DNA methylations that down-
regulated gene expression, and those that did not affect
gene expression. The former category might be related
to a tumorigenesis mechanism; thus, these methylations
should be studied biofunctionally and might represent
targets for tumor treatment, and the latter methylations
may be considered potential biomarkers for PC diagnosis.
Results
Wide-spread aberrant hypermethylation in PC and PN
revealed via genomic methylation profiling
The clinical characteristics of the patients enrolled in
this study are listed in Table 1. The whole-genome
methylation profiles of the PC and PN samples were
successfully identified using the methylCap-seq method.
Exogenous fully methylated and unmethylated spike DNA
fragments were used as controls to confirm the capture
accuracy of hypermethylated DNA fragments (Additional
file 1: Figure S1). We acquired 33,784,358 raw reads in the
PC group and 30,868,151 raw reads in the PN group.Based on their alignment with the human genome (hg19)
sequence, 16,267,025 (48.15%) raw reads in the PC group
and 15,033,135 (48.70%) raw reads in the PN group were
uniquely positioned. The reads mapping to 28,691 CGIs,
which were defined using the University of California,
Santa Cruz (UCSC) Genome Browser, were investigated:
3.57% of the reads in the PC group and 4.25% of the reads
in the PN group were positioned at CGIs, resulting in a
CGI coverage rate of 64.31% in the PC group and 64.36%
in the PN group. These data indicated that our experiment
provided considerable information regarding genomic
CGIs (Figure 1A).
Accumulation of the mapped reads formed peaks. In
total, 276,442 and 255,743 peaks were found in the PC
and PN samples, respectively, displaying distinct distri-
butions of hypermethylated regions between PC and PN
throughout the chromosomes (Figure 1B). An analysis of
the hypermethylated peaks approximately 5 kb from the
transcription start site (TSS) revealed that methylation
peaks accumulated near TSSs, and that more of these
peaks were detected in the PC group than in the PN
group (Figure 1C). After removing the peaks common
to both PC and PN samples (approximately 209,000),
66,807 PC-specific and 46,815 PN-specific hypermethy-
lated differently methylated regions (DMRs) were identi-
fied (Figure 1D). Of these hypermethylated DMRs,
36,959 PC-specific and 25,605 PN-specific DMRs were
located within genes (Figure 1E), and 1,131 hypermethy-
lated DMRs in PC tissue and 727 hypermethylated DMRs
in PN tissue were associated with CGIs. The hypermethy-
lated DMRs were separated into three categories: TSS,
intragenic or intergenic (Figure 1E). Subsequently, the
location of the TSS DMRs and intragenic DMRs were
further determined using structural annotations of the
human genome, such as downstream, enhancer, exon,
intron, miRNA, promoter, and 5′ UTR (Figure 1F).
This analysis yielded 1,859 DMRs that mapped to
CGIs in both the PC and PN samples, and these DMRs
represented the vast majority of the hypermethylated
CGIs in the refGene category for PC (88%) and PN
(87%); orphan CGIs, which are not associated with any
known refGene, accounted only for 12% (133 orphan
CGIs of 1,131 affected CGIs; Additional file 2: Table S1)
and 13% (96 orphan CGIs of 727 affected CGIs; Additional
file 3: Table S2) of the CGI-related DMRs in PC and PN
tissue, respectively (Figure 1G). There was no difference in
the frequency of orphan CGIs among the DMRs between
the PC and PN samples. When the gene-associated DMRs
were considered, 5,341 such DMRs were identified; we
found a higher frequency of CGI-containing promoters in
PC tissue (21%, 609/2,955; Additional file 4: Table S3) than
in PN tissue (13%, 312/2,386; Additional file 5: Table S4)
(Figure 1G), suggesting the importance of CGIs in
aberrant DNA methylation during PC tumorigenesis.
Table 1 Clinical profile of the PC patients recruited in this study









Number of patients 10 10 16 15
Sex
Male 6 (60.0%) 6 (60.0%) 1.000 12 (75.0%) 12 (75.0%) 0.638
Female 4 (40.0%) 4 (40.0%) 4 (25.0%) 4 (25.0%)
Age
>60 years 7 (70.0%) 7 (70.0%) 1.000 12 (75.0%) 12 (80.0%) 1.000
≤60 years 3 (30.0% 3 (30.0% 4 (25.0%) 3 (20.0%)
Tumor location
Head 7 (70.0%) 7 (70.0%) 1.000 13 (71.2%) 13 (86.7%) 1.000
Body and tail 3 (30.0% 3 (30.0% 3 (18.8%) 2 (13.3%)
Differentiation
Poor 4 (40.0%) 4 (40.0%) 1.000 3 (37.5%) 1 (20.0%) 1.000
Moderate 6 (60.0%) 6 (60.0%) 5(63.5%) 4 (80.0%)
High 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Tumor stage
I, II 7 (70.0%) 7 (70.0%) 1.000 6 (75.0%) 4 (80.0%) 1.000
III, IV 3 (30.0%) 3 (30.0%) 2 (25.0%) 1 (20.0%)
Tumor size
≤3 cm 6 (60.0%) 6 (60.0%) 1.000 6 (75.0%) 4 (80.0%) 0.638
>3 cm 4 (40.0%) 4 (40.0%) 2 (25.0%) 1 (20.0%)
Lymph node metastasis
Yes 8 (80.0%) 8 (80.0%) 1.000 7 (87.5%) 4 (80.0%) 1.000
No 2 (20.0%) 2 (20.0%) 1 (12.5%) 1 (20.0%)
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within a promoter is responsible for gene expression
silencing. However, two recent studies discovered that
certain types of tumor- and tissue-specific methylation
occur in CGI shores that play important biological roles.
In this study, aside from examining the methylation
status of CGIs, we investigated the methylation status of
CGI shores, particularly those associated with gene pro-
moters. Regarding the hypermethylated genes and their
sites of hypermethylation (in the CGI only, the CGI
shore only, or both) in PC tissue, 527 genes (Additional
file 6: Table S5) were hypermethylated in a CGI and a
CGI shore (502 DMRs); 111 genes (Additional file 7:
Table S6) were hypermethylated in a CGI alone (108
DMRs), and 1,278 genes (Additional file 8: Table S7)
were hypermethylated in a CGI shore alone (1.242
DMRs). In contrast, based on analysis of the hypermethy-
lated genes and sites of hypermethylation in PN tissue,
333 genes (Additional file 9: Table S8) were hypermethy-
lated in both a CGI and a CGI shore (305 DMRs), 51
genes (Additional file 10: Table S9) were hypermethylated
in a CGI alone (47 DMRs), and 1,298 genes (Additionalfile 11: Table S10) were hypermethylated in a CGI shore
only (1,183 DMRs) (Figure 1H). In general, the number of
genes aberrantly methylated in a CGI was much fewer, ac-
counting for 20% to 25% of the total genes affected. More
frequently, the genes were methylated in a CGI shore,
which is probably due to the extended genomic regions
defined by the CGI shore. We detected more abnormally
hypermethylated genes in a CGI in PC tissue than in PN
tissue (P = 0.0002, Chi-square test), suggesting that CGIs
are more likely to contain an aberrant DNA methylation
target during PC development.
Gene ontology (GO) and Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway analysis of the aberrantly
methylated genes in PC
It is well accepted that methylation abnormalities within
promoters can influence the expression of the corre-
sponding genes. Therefore, we conducted GO analysis of
the genes that displayed promoter hypermethylation in
PC and PN tissue. A significance of P < 0.05 indicated
gene enrichment in several GO categories (Table 2).
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Figure 1 (See legend on next page.)
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Figure 1 Data mining of MethylCap-seq libraries. (A) Experimental strategy to evaluate differential DNA methylation in PC compared with PN.
(B) Chromosomal view of genome-wide distribution of hypermethylated DNA in PC compared with PN. Red bar, hypermethylation in PC; green
bar, hypermethylation in PN. (C) Hypermethylated peaks around the TSS site in PC compared with those in PN. Peaks were surveyed in a broad
region (from 5 kb downstream to 5 kb upstream of the TSS). (D) Mapping peaks and differently methylated regions (DMRs) that were specific for
PC and PN. The DMRs are shown according to their inclusion in different gene structure context, such as refGene or CpG island (CGI) definitions.
Note that the y-axis is interrupted to show whole dataset. (E) Genomic distribution of DMRs with PC and PN in transcription start sites (TSSs),
intragenic regions, and intergenic regions. The total number of DMRs is presented at the top of each graph. (F) DMR distribution over the various
gene structures based on sole refGene involvement versus both CGI and refGene involvement in PC-specific and PN-specific DMRs. The genomic
context is defined as that found in the UCSC database. (G) PC- and PN-selective DMR distribution over orphan CGIs versus refGene-related CGIs,
and over CGI-containing promoters vs. no-CGI promoters. (H) DMRs (and their related genes) in PC and PN, considering the involvement of various
CGI features (CGI, CGI shore, or both). CGI, CpG island; DMR, differently methylated regions. PC, pancreatic cancer; PN, adjacent non-tumor tissue; TSS,
transcription start site.
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‘sequence-specific DNA binding’ (GO:0043565), ‘neuron
differentiation’ (GO:0030182), ‘regulation of transcription,
DNA-dependent’ (GO:0006355), or ‘cell morphogenesis
involved in differentiation’ (GO:0000904) and that 383
hypermethylated genes in PN tissue (Additional file 13:
Table S12) were enriched in ‘plasma membrane part’
(GO:0044459), ‘channel regulator activity’ (GO:0016247),
‘positive regulation of bone morphogenetic protein
(BMP) signaling pathway’ (GO:0030513), ‘protein homo
oligomerization’ (GO:0051260), or ‘neuron differentiation’
(GO:0030182). Furthermore, we identified 111 genes
containing hypermethylated promoters in PC that were
enriched in ‘regulation of transcription term’; among these
genes, the methylation status of DLX4, ELAVL2, IRX1,
PITX2, SIM2, TBX5, and TFAP2C was subsequently
validated in the tissue samples by methylation-specific
PCR (MSP) (Figure 2B).
A KEGG pathway analysis of the aforementioned
genes revealed that hypermethylated genes in both PC
and PN tissue were enriched in ‘neuroactive ligand-
receptor interaction’ (hsa04080) (Table 2). Furthermore,
several miRNAs were aberrantly methylated in PC tis-
sue. The PC-related hypermethylated miRNAs included
mir-9-3, mir-9-1, mir-124-3, mir-10b, mir-124-2, mir-718,
and mir-203; the PN-related hypermethylated miRNAs
included mir-210, mir-1469, mir-130b, mir-149, mir-1224,
and mir-564 (Table 3).
We analyzed the hypermethylated genes that were
enriched in PC and PN tissue, focusing on their func-
tional involvement in tumorigenesis, and found that the
aberrantly methylated genes could be categorized as
either tumor promoters or tumor suppressors. The cor-
responding genes included 20 tumor promoters and 10
tumor suppressors among the PC-related hypermethy-
lated genes and 10 tumor promoters and 5 tumor sup-
pressors among the PN-related hypermethylated genes
(Additional file 14: Table S13). These results suggest that
aberrant DNA methylation plays an important role in
tumor development via the important biological pathways
related to the regulation of tumorigenesis.Verification of PC-specific DMRs identified in methylCap-seq
The accuracy and precision of the DMR profiles were
validated in two sample sets, which consisted of the
pooled samples used to generate the methylCap-seq li-
brary and another independent sample set. In one valid-
ation vignette, the DNA methylation status of the ten
most significant DMRs that were located in a promoter
region (P <10−15) were evaluated using bisulfite sequen-
cing PCR (BSP) in the same set of PC and PN samples
used to generate the methylCap-seq libraries. Six candidate
DMR genes, C5orf38, EMX1, NPR3, VSTM2B, ELAVL2,
and TFAP2C, were validated to be significantly hyper-
methylated in PC tissue compared with PN tissue using
the BSP technique (representative results are shown in
Figure 2A).
Preliminary detection of the DMRs identified by genome
methylation profiling in limited clinical PC samples
In another validation vignette, the methylation status of
20 gene-associated DMRs scattered throughout various
genetic elements, such as promoters, miRNAs, introns,
exons, and CGI shores, were analyzed using MSP in
paired samples of PC and PN tissue. The results revealed
that seven gene-associated DMRs displayed clear differ-
ences in methylation between the PC and PN samples
(representative results are shown in Figure 2B). The
DMRs in the promoter regions of TRADD, AGAP2, and
FAM115A displayed a loss of methylation in PC tissue
(The MSP results are presented in Additional file 15:
Table S14).
MSRE-qPCR and RT-qPCR validation of the methylation of
orphan CGIs and the expression of corresponding ESTs in
PC cell lines treated with 5-aza-2′-deoxycytidine (5-aza-dc)
Three PC cell lines were treated with 5-aza-2′-
deoxycytidine (5-aza-dc). The methylation status of ten
hypermethylated DMRs (for gene locus information, see
Figure 3A) in promoter CGIs and orphan CGIs was
quantitatively analyzed via methylation sensitive restric-
tion enzyme-based qPCR (MSRE-qPCR) (Figure 3B) in
these three PC cell lines before and after treatment with






Hypermethylated promoter related gene (615) GOTERM_MF_FAT GO:0043565 sequence-specific DNA binding 61 607 8.47 × 10−16
GOTERM_BP_FAT GO:0030182 neuron differentiation 47 438 5.06 × 10−13
GOTERM_BP_FAT GO:0006355 regulation of transcription,
DNA-dependent
111 1773 5.08 × 10−13
GOTERM_BP_FAT GO:0000904 cell morphogenesis involved
in differentiation
29 244 3.07 × 10−9
GOTERM_BP_FAT GO:0006928 cell motion 41 475 1.30 × 10−8
GOTERM_BP_FAT GO:0007267 cell-cell signaling 47 600 1.88 × 10−8
GOTERM_CC_FAT GO:0043005 neuron projection 31 342 4.13 × 10−8
GOTERM_CC_FAT GO:0045202 synapse 28 355 3.28 × 10−6
GOTERM_CC_FAT GO:0044459 plasma membrane part 96 2203 9.52 × 10−6
GOTERM_CC_FAT GO:0005887 integral to plasma membrane 60 1188 1.40 × 10−5
GOTERM_CC_FAT GO:0044456 synapse part 21 246 2.43 × 10−5
GOTERM_MF_FAT GO:0022836 gated channel activity 24 310 1.03 × 10−4
GOTERM_MF_FAT GO:0005021 vascular endothelial growth factor
receptor activity
4 8 1.48 × 10−3
GOTERM_MF_FAT GO:0003702 RNA polymerase II transcription
factor activity
18 244 1.61 × 10−3
GOTERM_MF_FAT GO:0030955 potassium ion binding 12 128 2.12 × 10−3
KEGG_PATHWAY hsa04080 neuroactive ligand-receptor interaction 17 256 3.33 × 10−3
Hypomethylated promoter related gene (383) GOTERM_CC_FAT GO:0044459 plasma membrane part 63 2203 2.05 × 10−5
GOTERM_MF_FAT GO:0016247 channel regulator activity 6 59 3.00 × 10−3
GOTERM_BP_FAT GO:0030513 positive regulation of BMP
signaling pathway
3 6 4.06 × 10−3
GOTERM_BP_FAT GO:0051260 protein homooligomerization 7 95 5.36 × 10−3
GOTERM_BP_FAT GO:0030182 neuron differentiation 16 438 7.41 × 10−3
GOTERM_BP_FAT GO:0048732 gland development 8 135 7.90 × 10−3
GOTERM_BP_FAT GO:0031328 positive regulation of cellular
biosynthetic process
21 685 1.19 × 10−2
GOTERM_CC_FAT GO:0005902 microvillus 4 36 2.28 × 10−2
GOTERM_CC_FAT GO:0032420 stereocilium 3 15 2.60 × 10−2
GOTERM_CC_FAT GO:0032421 stereocilium bundle 3 17 3.30 × 10−2
GOTERM_MF_FAT GO:0016524 latrotoxin receptor activity 2 2 3.32 × 10−2
GOTERM_CC_FAT GO:0005923 tight junction 5 73 3.54 × 10−2
GOTERM_MF_FAT GO:0003700 transcription factor activity 25 975 3.60 × 10−2
GOTERM_MF_FAT GO:0005261 cation channel activity 10 275 4.12 × 10−2
*Logarithmic transformation of P to show significance level of the differential methylation region (in differently methylated region (DMR) estimation) or methylation
blocks (model-based analysis of ChIP-Seq). The higher this value, the higher the probability inferred for DMR or methylation blocks.
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containing genes and orphan CGI-containing expressed
sequence tags (ESTs) were analyzed using RT-qPCR to
ascertain the correlation between the aberrant DMRs
and the corresponding mRNA expression levels (Figure 3C).
The results indicated that the methylation levels of four
orphan CGIs and one promoter CGI were decreased
and that the mRNA expression of the correspondinggenes or ESTs increased upon 5-aza-dc treatment, sug-
gesting that the expression of these genes or ESTs might
be regulated by DNA methylation. Quantitative analysis
of the methylation status of these particular DMRs in an
independent set of samples (testing group: eight PC
samples, five PN samples, and three PC cell lines) con-
firmed the differences in methylation at these four
DMRs in the clinical samples (Figure 3D).
Figure 2 (See legend on next page.)
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Figure 2 Representative results of bisulfite sequencing PCR (BSP) and methylation-specific PCR (MSP) validation of methylCap-seq
data. For each gene, the UCSC scheme of the gene locus and the examined promoter regions are shown. (A) BSP results. (B) MSP results. 15
pairs of PC and PN samples (1,2,3,4,5,6,7,8,9,10,11,12, 307,311,313) and an extra 1 PC (314) were evaluated. All the samples were assayed by MSP.
GAPDH: GAPDH-BSP were amplified as quality and quantity control for the confirmation of bisulfite-converted DNA templates. N, negative control;
P, positive control; PC, pancreatic cancer; PN, adjacent non-tumor tissue.
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Pooling strategies have been utilized in many previous
genomic studies to investigate the phenotypic similarities
between specific models, owing to the advantage of
conserving samples [12,13]. In this study, genome-wide
methylation profiles of PC and PN tissues were estab-
lished using corresponding pooled samples.
We identified 5,280 and 3,488 hypermethylated DMRs
in PC and PN tissue, respectively, that were closely asso-
ciated with genes and CGIs. Gene ontology analysis of
the genes associated with these DMRs revealed that the
aberrantly hypermethylated genes primarily belonged to
categories related to nucleic acid binding, DNA binding,
and activation of transcription factors, suggesting that
the methylation of these affected genes coupled with the
downregulation of RNA expression resulted in the de-
creased expression of other genes. Studies of non-small-
cell lung carcinoma by Helman et al. [14] and Zhao et al.
[15] demonstrated that methylation-enriched genes dis-
played aberrant methylation and RNA expression in mul-
tiple tumor types; these genes were referred to as tumor
suppressor genes. The methylation-enriched genes in PC
associated with ‘cell morphogenesis involved in differenti-
ation’ (GO: 0000904) may participate in the morphological
changes and late-stage differentiation in PC tissue. In
contrast, the hypermethylated genes in PN tissue were
predominantly enriched in ‘plasma membrane part’Table 3 Aberrantly hypermethylated miRNAs in PC and PN in














*Logarithmic transformation of P to show significance level of the differential methylat
blocks (model-based analysis of ChIP-Seq). The higher this value, the higher the proba(GO:0044459) and ‘channel regulator activity’ (GO:0016247),
and it has been confirmed that these genes are enriched
in other tumor types in genomic methylation studies,
suggesting that abnormal formation of the plasma mem-
brane might be a common characteristic of tumor
differentiation and maintenance [16,17].
We also conducted KEGG pathway analysis of the
genes containing DMRs in their promoter; surprisingly,
the hypermethylated genes in both the PC and PN sam-
ples were enriched in the same pathway, ‘neuroactive
ligand-receptor interaction’, which primarily participates
in the endocrine and exocrine functions of cells. Func-
tional abnormalities in these genes have been demon-
strated in studies of meningioma and PC [18,19]. Our
study revealed the identical direction of methylation
changes in this pathway in PC and PN tissue, but the de-
tailed mechanism by which this pathway participates in
PC development requires further investigation (Table 2).
As epigenetic factors, miRNAs play an important role
in the regulation of cellular biophysical functions, and
have been shown to be associated with the apoptosis,
invasion, metastasis, recurrence, and drug resistance of
tumor cells. The regulation of miRNAs by DNA methy-
lation has been extensively studied. In this study, we
identified particular miRNAs that were aberrantly methyl-
ated in PC tissue. Among these miRNAs, hsa-mir-124-3
has been shown to be hypermethylated in PC and ispresent and previous studies
ion in genome −10log (P)* Transcription direction References
2 78.11 Sense [24]
92 81.02 Antisense [25]
0 30.36 Sense [21]
40 366.4 Sense [28,29]
3 387.77 Sense [20,26]
04 65.44 Antisense
01 92.85 Sense [27]
95.42 Antisense [23]
1 81.68 Sense




ion region (in differently methylated region (DMR) estimation) or methylation
bility inferred for DMR or methylation block.
Figure 3 Methylation of CGIs (orphan CGIs or regular CGIs) might influence the expression of putative ESTs or mRNAs. (A) UCSC scheme of
CGIs and the nearby putative ESTs or mRNAs analyzed in this study. (B) DNA methylation changes in PC cell lines after treatment with 5-aza-dc. The
GAPDH-BSP product serves as a quality and quantity control for the bisulfite-converted DNA templates. (C) EST expression after 5-aza-dc treatment
determined by RT-qPCR. GAPDH mRNA expression was the loading control. (D) Quantitative analysis of DNA methylation by methylation sensitive
restriction enzyme-based qPCR (MSRE-qPCR) in eight PC and five PN samples. The box is defined by 25% and 75% quantiles. The methylation levels in
the PC and PN samples were compared by one-way analysis of variance (ANOVA), and the P values are indicated. 5-AZ, 5-aza-2′-deoxycytidine; DMSO,
dimethyl sulfoxide; EST, expressed sequence tag; N, negative control; P, positive control; PC, pancreatic cancer; PN, PN, adjacent non-tumor tissue.
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PC [20,21]. Alternatively, mir-130b and mir-210 are two
hypermethylated miRNAs in PN tissue that were discov-
ered in this study, both of which were found to be more
strongly expressed in PC and have been associated with
the proliferation and invasion of PC cells [22,23]. Certain
miRNAs that we identified as aberrantly methylated in PC
tissue have already been studied in other tumor types
and are regulated by DNA methylation. For example,
the hypermethylated miRNAs identified in PC tissue,
such as miR-9-3, mir-9-1, miR-124, and miR-203, are
also hypermethylated in non-small-cell lung carcinoma,
breast cancer, cervical cancer, and hematological cancer,
respectively; hypermethylation of these sites decreases
miRNA expression, which promotes tumor development
and tumor cell proliferation [24-27]. In addition, mir-10b,
which was found to be hypermethylated in PC tissue in
this study, was thought to be an inhibitor of tumor
metastasis in animal models [28] and was found to be
more strongly expressed in PC [29]. Therefore, furtherinvestigation of the remaining miRNAs that were aber-
rantly methylated in PC will shed light on the mechanisms
underlying pancreatic carcinogenesis, as the related re-
search is currently very limited.
The top 40 genes, based on their P value, that
contained methylation changes in their promoter region
were selected and examined using MSP in the test group
samples. Of these genes, 18 displayed significant differ-
ences in methylation between PC and PN tissues (or PC
cell lines). Interestingly, among these genes, seven (DLX4,
ELAVL2, IRX1, PITX2, SIM2, TBX5, and TFAP2C) were
enriched for the annotation of regulation of transcription
(GO: 0006355), which corresponds to the results obtained
in our previous GO analysis. All of the genes discussed
above have been investigated in PC and other tumor
types, and their involvement in carcinogenesis has been
confirmed.
At both the genetic and genomic levels, many hyper-
methylated genes previously reported in PC studies
were identified as hypermethylated DMRs in the present
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CEBPA [31], CACNA1G [32], CCND2 [33], BAI1, NRN1,
PENK, FAM84A, and ZNF415 [6]. In addition, our study
identified other genes that are frequently hypermethylated
in different types of cancer, such as RASSF1a, CDKN2A,
hHML1, and CDH1 [34,35]. Thus, we have established a
relatively extensive database of abnormally methylated
sites in PC. We also compared our data with those
reported by Omura et al. [6], who analyzed nine pairs of
PC and PN samples using human CGI microarray 244 k
chips, obtaining (after data filtering using the appropriate
thresholds) 1,658 differently methylated known loci.
This comparison revealed the following. (1) Regarding
the ability to capture aberrantly methylated gene targets,
methylCap-seq identified more hypermethylated genes
than the array method in PC tissue (1983 versus 1206)
and PN tissue (1692 versus 379), indicating that methyl-
ated DNA fragment enrichment followed by deep sequen-
cing identifies additional aberrant gene loci, although it is
more labor-intensive and time-consuming. (2) A total of
737 genes (Additional file 16: Table S15) was identified by
both the methylCap-seq and array methods, accounting
for 46.7% of the total genes recovered. This high recovery
rate between the two methods reflects the reliability of
these methods for this purpose. However, the unique
genes that were identified suggest that these two methods
each have their own particular advantages. (3) The high
percentage of commonality among the PC-specific
hypermethylated DMR genes (46.2%) and low percentage
of commonality among the PN-specific hypermethylated
DMR genes (30 genes, 2.9% of all the PN-related hyper-
methylated DMR genes) (Additional file 17: Table S16)
between the study of Omura et al. [6] and this study
suggests that during the entire process of PC development,
hypermethylation is a relatively defined and destined
process, whereas hypermethylation at the initiation of
tumorigenesis is relatively random or perhaps stochastic.
We also compared our aberrant methylated gene targets
determined in this study with the results of previous stud-
ies. Among all 3,911 differently methylated genes (DMGs)
identified in this study, 728 DMGs were reported by
Nourse et al. [36], 339 DMGs were reported by Vincent
et al. [7], and 55 DMGs were reported by Tan et al. [37]
(Additional file 18: Table S17). This discrepancy in the
number of DMGs obtained between the four groups
might result from the different technological platforms
adopted by each study group, as well as the different
ethnic backgrounds of the enrolled patients. Furthermore,
this discrepancy emphasizes that the array-based and
sequencing-based DNA methylation assay methods must
be applied alternately to complement one another, to
elucidate DNA methylation at the genomic level.
Deaton and Bird separated CGIs into three categories,
TSS, intragenic, and intergenic, with the latter twocategories defined as orphan CGIs [38]. Despite poor
understanding of the functions of orphan CGIs until
recently, studies have shown that orphan CGIs are in-
volved in the regulation of gene transcription, genomic
imprinting, and non-coding RNA transcription and that
orphan CGIs might display tissue-specific methylation
profiles [39]. In this study, we investigated the methyla-
tion status of particular orphan CGIs in PC. Hyper-
methylated orphan CGIs have been found in PC. The
methylation status of orphan CGIs was closely associated
with the transcription levels of nearby non-annotated
ESTs. Further studies should be conducted to clarify
whether the methylation-regulated ESTs containing or-
phan CGIs are potential genes or gene elements. It is well
known that merely 6.8% of CpGs are located in CGIs. The
methylation status and biological functions of the other
93.2% of CpGs have yet to be adequately studied. The
study by Yu et al. [40] indicated that the methylation of
CpGs in CGI shores is involved in regulating gene tran-
scription or establishing tissue-specific methylation pat-
terns, and changes in the methylation status of CpGs in
CGI shores might occur at an earlier stage in carcinogen-
esis than the changes that occur in gene-associated CGIs.
Our study suggests that the methylation changes in all of
these CpG regions in PC are indispensable components of
the genomic methylation profile of PC and may influence
the transcription of PC-related genes and non-coding
RNAs, potentially affecting tissue-specific cell differenti-
ation and ultimately leading to carcinogenesis.
It is generally accepted that abnormal DNA hyperme-
thylation can either downregulate gene expression (gene
silencing) or exert no influence on gene expression.
Gene silencing-related DNA methylation might be in-
volved in PC development, and, therefore, these methy-
lation sites may be examined in tumor development
studies and considered as treatment targets. Alterna-
tively, the DNA methylations that are not associated
with gene expression might serve as biomarkers of the
specific state of PC, and, therefore, these methylation
sites could be used for clinical diagnosis. We anticipate
that our comprehensive analysis of PC gene methylation
will facilitate the further investigation of PC biomarkers
for diagnostic, prognostic, and therapeutic applications,
by: (1) improving the understanding of the epigenetic
importance of DNA methylation in PC tumorigenesis,
which might be located outside or within CGIs, including
both orphan and gene-associated CGIs; and (2) providing
additional candidate targets for PC diagnosis, prognosis
and treatment (not limited to the previously reported
CGIs and promoters). Moreover, the enormous number of
targets (many thousands) obtained suggests a vast hetero-
geneity among PC patients, thus requiring a large patient
cohort for chip-based analyses to validate, optimize, and
establish potential targets for ultimate clinical application.
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In the present study, the genome-wide methylation
profiles of PC and PN tissues were established using
methylCap-seq, revealing globally reprogrammed and
deregulated DNA methylation in PC. Compared with
PN tissue, there were many PC-specific aberrations in
the hypermethylation of CpGs in TSS CGIs, orphan
CGIs, CGI shores, and promoter regions lacking CGIs.
These findings will be helpful in elucidating the mecha-
nisms underlying pancreatic carcinogenesis related to
the DNA methylation-regulated expression of genes and
non-coding RNAs. Furthermore, the aberrantly methyl-
ated genes in PC identified in this study might serve as
potential biomarkers for the early diagnosis and treat-
ment of this deadly disease.
Methods
Clinical samples
Pancreatic cancer tissue samples were collected from 18
patients who had undergone surgical treatment without
receiving preoperative chemotherapy or radiotherapy
from May 2009 to March 2011 in Renji Hospital, School
of Medicine, Shanghai Jiao Tong University. A diagnosis
of PC was confirmed by histological examination. Resected
tumor tissues and matched normal tissues at least 2 cm
away from the tumor tissues were collected during the op-
eration, labeled, and stored at −80°C. The sixth edition of
the Tumor, Node, and Metastasis (TNM) Staging System
proposed by the International Union against Cancer [41]
was utilized to stage the tumor tissue samples (Table 1).
The study was approved by the medical ethics committee
at Renji Hospital, School of Medicine, Shanghai Jiao Tong
University. All the patients signed an informed consent
form. DNA was isolated from frozen tissues or cell lines
using a conventional proteinase K and organic extraction
method, as previously described [42].
Genome-wide methylation profiling by methylCap-seq
Genomic DNA was extracted from ten PC tissues and
ten matched normal tissues. Equal amounts of DNA
were mixed to form the PC and PN groups. Pooled
DNA (1.2 μg) from each group was used to generate the
library for methylCap-seq as previously described [42].
Mapping the sequence reads and DMR identification and
annotation
We used Burrows-Wheeler alignment tools [43] with the
default settings to map the 36 bp unpaired reads to the
hg19 human genome reference assembly [44]. After re-
moving PCR duplicates using Picard, the aligned data
were converted, sorted, and indexed using Samtools [45]
and Picard [46].
Methylation peaks (hypermethylated regions) were
identified using model-based analysis of ChIP-Seq in thePC and PN samples, as previously described [42]. The
DMRs between PC and PN were identified using two
methods, model-based analysis of ChIP-Seq [47] and a
bi-asymmetric-Laplace model (BALM) [48], to increase
the detective power of methylCap-seq. To decrease the
false positive detection of DMR using BALM, the dual-
threshold strategy was applied. A high-confidence thresh-
old (0.975) was utilized in the PC hypermethylated region
screening, and a low-confidence threshold (0.950) was
utilized in the PN hypermethylated region screening.
Cancer-specific methylation peaks were defined as hyper-
methylated regions. Similarly, normal tissue-specific methy-
lation peaks were defined as hypomethylated regions with
the reverse settings. Whole-genome methylation (methyla-
tion of each CpG) was inferred using BALM, which was
processed for a Pearson correlation analysis among all the
samples in the R environment. The refSeq genes (UCSC
genes) and corresponding CGIs were downloaded from
the table browser of the UCSC database [42]. The
browser extensible data (BED) file operations were per-
formed using BEDTools [49] and other Perl scripts. All
the scripts are available upon email request. The generated
genomic methylation profile was uploaded to a public
database (Gene Expression Omnibus: GSE54854). Gene
ontology analysis was performed using DAVID Bioinfor-
matics Resources 6.7 [50].Methylation analysis
In this study, BSP was utilized to determine the methyla-
tion status at single CpG resolution of DMRs identified
by genomic methylation profiling; MSP was performed
for qualitative methylation screening in a small set of PC
samples. Using MSRE-qPCR, the DNA methylation
status in orphan CGIs was quantitatively analyzed in
PC cell lines before and after 5-aza-2′-deoxycytidine
treatment and in small samples of clinical PC tissues, as
described previously [51]. Approximately 1.0 μg of gen-
omic DNA extracted from PC or PN samples or PC cell
lines was bisulfate-treated using EpiTect Kit (Qiagen,
Hilden, Germany). Primers for MSP and BSP were de-
signed using MethPrimer, an online primer design tool
[52]. The MSRE-qPCR primers were designed using
Primer3 [53]. The sequences of the primers utilized in
this study are listed in Additional files 19 and 20: Tables
S18 and S19. Jumpstart Taq (Sigma-Aldrich, St. Louis,
MO, USA) was used in BSP and MSP with a 20 μl reac-
tion volume per tube. The BSP and MSP reaction condi-
tions were as follows: 94°C for 3 min; 35 cycles of 94°C
for 20 s, annealing for 20 s, and 72°C for 20 s; and 72°C
for 5 min. The PCR products were analyzed by electro-
phoresis in 1.5% agarose gels. The PCR products were
TA cloned and verified by sequencing. At least five
clones were sequenced for each BSP reaction.
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Three pancreatic adenocarcinoma cell lines were used:
BxPC-3 ATCC, CRL-1687), PANC-1 (ATCC, CRL-1469),
and CFPAC-1 (ATCC, CRL-1918). All the cell lines were
cultured in RPMI1640 supplemented with 10% FBS, 100
U/ml penicillin, and 100 U/ml streptomycin. All the cell
lines were maintained at 37°C in a humidified atmosphere
with 5% CO2.
The restoration of gene expression by demethylation
was evaluated in the BxPC-3, CFPAC-1, and CFPAC-1
cell lines. For the CpG demethylation analysis, exponen-
tially growing cells were seeded at a density of 1.5 × 106
cells/100 mm dish and allowed to attach overnight. The
cells were then treated with freshly prepared 5-aza-dC
(5.0 μM; Sigma-Aldrich, St. Louis, MO, USA) for 3 days.
RNA isolation and real-time PCR
Total RNA was prepared from cultured cells using Trizol
reagent according to the manufacturer’s instructions
(Invitrogen, USA) and then reverse transcribed using an
oligo (dT) primer and SuperscriptII RNase H-Reverse
Transcriptase (Invitrogen, USA). Real-time PCR was
performed with primer pairs for the EST expression
assay, and GAPDH was used as the internal control.
Real-time PCR was performed as follows: 94°C for 3 min
followed by 40 cycles of 94°C for 10 s, 62°C for 10 s, and
72°C for 15 s. Real-time qPCR was performed to detect
GAPDH expression with an SYBR Green PCR Kit (Applied
Biosystems, Foster city, CA, USA) on a ROTOR-GENE
6000 Real-Time PCR System (ROTOR-GENE).
Statistical analysis
Statistical calculations were performed using the SPSS
statistical software package (Version 13.0; SPSS, Inc.
Chicago, IL). The measurement data were analyzed using
one-way ANOVA. Statistical significance was considered
for P < 0.05.
Additional files
Additional file 1: Figure S1. External and internal control DNA
validation of MBD enrichment in a hypermethylated DNA fragment. (A)
Spike DNA (containing fully methylated and unmethylated exogenous
DNA fragments) was added to the pooled DNA samples. The methylated
spike DNA appeared in the elution fraction containing more than 600 mM
NaCl, and the unmethylated spike DNA appeared in the run-through
fraction. This procedure was adopted to confirm the accuracy of methylated
DNA enrichment in the present study. (B) Internal gene target control. As
with the principle of spike DNA, internal gene targets that display a gradient
of methylation statuses, such as GAPDH (unmethylated), CFTR (moderately
methylated), and TP63 (highly methylated), were used to evaluate the
methylated DNA enrichment process. Here, we show that GAPDH rapidly
eluted in the run-through fraction, TP63 eluted in the 1000 mM NaCl
fraction, and CFTR eluted in a fraction between these two extremes.
Both the spike DNA and the internal control gene targets confirmed the
accuracy of methylated DNA enrichment in this study. PC, pancreatic
cancer; PN, non-tumor tissue adjacent to pancreatic cancer.Additional file 2: Table S1. PC-related hypermethylated DMR in
orphan CGIs.
Additional file 3: Table S2. PN-related hypermethtylated DMR in
orphan CGIs.
Additional file 4: Table S3. PC-related hypermethylated genes that
lack CGIs in their promoters.
Additional file 5: Table S4. PN-related hypermethylated genes that
lack CGIs in their promoters.
Additional file 6: Table S5. PC-related hyper-DMRs and the involved
genes that were affected via both CGIs and CGI shore.
Additional file 7: Table S6. PC-related hyper-DMRs and the involved
genes that were affected via CGIs alone.
Additional file 8: Table S7. PC-related hyper-DMRs and the involved
genes that were affected via CGI shores alone.
Additional file 9: Table S8. PN-related hyper-DMRs and the involved
genes that were affected via both CGIs and CGI shores.
Additional file 10: Table S9. PN-related hyper-DMRs and the involved
genes that were affected via CGIs alone.
Additional file 11: Table S10. PN-related hyper-DMRs and the involved
genes that were affected via CGI shores alone.
Additional file 12: Table S11. PC-related hypermethylated CGI in gene
promoters.
Additional file 13: Table S12 PN-related hypermethylated CGI in gene
promoters.
Additional file 14: Table S13. The effects of PC- and PN-related hyper-
methylated genes on tumorigenesis.
Additional file 15: Table S14. MSP validation of 20 targets in clinical
samples and cell lines.
Additional file 16: Table S15. PC-related hypermethylated genes (loci)
recovered by both methylCap-seq and microarray 244 k chip.
Additional file 17: Table S16. PN-related hypermethylated genes (loci)
recovered by both methylCap-seq and microarray 244 k chip.
Additional file 18: Table S17. Gene symbol of genes aberrantly
methylated in our study and previous studies.
Additional file 19: Table S18. Analysis of aberrant methylation in
pancreatic cancer by BSP and MSRE-qPCR.
Additional file 20: Table S19. BSP, MSRE-qPCR, and MSP primers used
in this study.Abbreviations
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